Last $28.52 USD
Change Today +0.89 / 3.22%
Volume 293.3K
QDEL On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 5:20 PM 12/22/14 All times are local (Market data is delayed by at least 15 minutes).

quidel corp (QDEL) Snapshot

Open
$27.80
Previous Close
$27.63
Day High
$28.57
Day Low
$27.43
52 Week High
01/15/14 - $32.24
52 Week Low
04/24/14 - $19.21
Market Cap
982.0M
Average Volume 10 Days
450.8K
EPS TTM
$-0.29
Shares Outstanding
34.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for QUIDEL CORP (QDEL)

Related News

No related news articles were found.

quidel corp (QDEL) Related Businessweek News

No Related Businessweek News Found

quidel corp (QDEL) Details

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, women’s health, and gastrointestinal diseases. The company offers Sofia analyzer, a fluorescent immunoassay system for hospitals, medical centers, and small clinics; various molecular assays, which run on thermocyclers; Sofia influenza A+B and QuickVue influenza tests for the detection of the viral antigens of influenza type A and B; and Sofia strep A fluorescent immunoassay and QuickVue Strep A tests for the detection of group A Streptococcal antigen from throat swabs. It also provides Sofia RSV and QuickVue RSV tests for respiratory syncytial virus; cell culture and DFA detection solutions for the detection of various viral respiratory pathogens; and various traditional cell lines, specimen collection devices, media, and controls for the use in laboratories. In addition, the company offers ELVIS HSV, a cell culture system for the isolation and detection of herpes simplex virus types 1 and 2; and multiplex cell culture solution. Further, it provides Quidel Molecular Direct clostridium difficile assay; Sofia hCG fluorescent immunoassay and QuickVue pregnancy tests, which are used for the detection of hCG in serum or urine for the early detection of pregnancy; Thyretain for the differential diagnosis of Graves disease; and QuickVue Chlamydia test for the detection of Chlamydia trachomatis. Additionally, the company offers QuickVue test, a fecal immunochemical test to detect the presence of blood in stool specimens; indirect fluorescent antibody products; serological test that measures antibodies circulating in the blood; and diagnostic and research products for oncology, bone health, and autoimmune diseases. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.

572 Employees
Last Reported Date: 02/27/14
Founded in 1979

quidel corp (QDEL) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $509.1K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $313.2K
Senior Vice President of Commercial Operation...
Total Annual Compensation: $307.0K
Senior Vice President of Clinical & Regulator...
Total Annual Compensation: $297.5K
Senior Vice President of Business Development...
Total Annual Compensation: $329.0K
Compensation as of Fiscal Year 2013.

quidel corp (QDEL) Key Developments

Quidel Corp. Receives Simultaneous FDA Clearance and CLIA Waiver for Sofia(R) Strep A+ Fluorescent Immunoassay

Quidel Corporation announced that it has received marketing clearance and CLIA waiver by the United States Food and Drug Administration (FDA) for its Sofia Strep A+ Fluorescent Immunoassay (FIA) for the rapid detection of infections by Group A Streptococcus bacteria. These bacteria are the most common cause of bacterial pharyngitis and can also cause rheumatic fever and other potentially serious illnesses. Sofia is the brand name for Quidel's next-generation, immunoassay system. The Sofia Analyzer and Sofia Strep A+ FIA combine unique immunofluorescence chemistry, advanced lateral flow technology, and failure alert and fail-safe systems designed to ensure reliable, objective, highly accurate, diagnostic results within five (5) minutes of application of the patient's specimen. The linked-FDA clearance and CLIA waiver represent the first such achievement of any manufacturer under the FDA's new Dual Submission Program. This program requires a Pre-submission, and allows for simultaneous review of the 510(k) and CLIA waiver applications, substantially reducing the time and effort required for the FDA's review of 510(k) and CLIA waiver submissions that previously required two independent sequential submissions. Successful passage through the Dual Submission Program thus allows the diagnostic industry to pursue its commercial goals sooner, while also more quickly bringing new products to the marketplace where they can serve both physicians and patients. The CLIA waiver designation for the Sofia Strep A+ FIA allows Quidel to sell the assay to all CLIA categories of laboratories in the United States, including the CLIA-waived segment of the market that is comprised of approximately 30,000 physician offices laboratories and 5,000 hospital emergency departments. It is anticipated that the clearance and CLIA waiver of the Sofia Strep A + FIA will further expand the placement of new Sofia instruments a process that has accelerated throughout 2014.

Quidel Receives FDA Clearance for its AmpliVue(R) Hand-Held Molecular Diagnostic Test for Bordetella Pertussis

Quidel Corporation announced that it has received clearance from the United States Food and Drug Administration to market its AmpliVue Bordetella Assay for the detection of Bordetella pertussis nucleic acids isolated from nasopharyngeal swab specimens obtained from patients suspected of having a respiratory tract infection attributable to Bordetella pertussis. The AmpliVue Bordetella Assay is an easy-to-use, self-contained, handheld disposable molecular diagnostic test with superb clinical accuracy. The assay requires no upfront extraction of DNA and generates an accurate result in approximately 75 minutes. Like all FDA-cleared AmpliVue assays, the AmpliVue Bordetella Assay is CLIA-classified as moderately complex and does not require the customer to invest in expensive thermocycling equipment. This benefit, plus less laboratory space requirements, can significantly lower a laboratory's cost when adopting new molecular testing methods. Quidel's AmpliVue platform now enables laboratories of all sizes to perform highly sensitive and specific molecular tests. The AmpliVue Bordetella Assay expands to six the list of detectable analytes for which this novel AmpliVue platform now has FDA clearance. These include Pertussis, C. difficile, Group A Strep, Group B Strep, HSV1 and HSV2.

Quidel Seeks Acquisitions

Quidel Corp. (NasdaqGS:QDEL) is looking for acquisition opportunities. Quidel proposed underwritten public offering of $150 million and intends to use the net proceeds from this offering for working capital and other general corporate purposes, which may include acquisitions of products, technologies or businesses, and opportunistic repurchases of shares of its common stock.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QDEL:US $28.52 USD +0.89

QDEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Analogic Corp $86.43 USD -0.07
Luminex Corp $18.82 USD +0.36
Meridian Bioscience Inc $17.04 USD +0.08
OraSure Technologies Inc $10.51 USD -0.02
Volcano Corp $17.89 USD +0.01
View Industry Companies
 

Industry Analysis

QDEL

Industry Average

Valuation QDEL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.7x
Price/Book 4.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUIDEL CORP, please visit www.quidel.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.